Amrita Vishwa Vidyapeetham has announced the AEEE Phase 2 results, accessible on amrita.edu. Candidates can now download their rank cards, which contain crucial details like overall rank and ...

2 20 Cedar Rapids Cooper Simon 5.10.5 155 2007-09-20 C Menomonee Falls, WI Brookfield HS Stars 2 21 Tri-City Bode Wise 6.00 189 2006-05-31 RD Windber, PA Shreveport Mudbugs 2 22 Madison ...

Chennai Metro Rail, which has been focusing on building the ₹63,246 crore phase II project, will first launch the Poonamallee - Porur stretch later this year and Porur - Vadapalani - Kodambakkam ...

Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, SRF388) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients ...

Idiopathic Pulmonary Fibrosis (IPF) is a progressive, irreversible, and fatal interstitial lung disease characterized by fibrotic remodeling of lung tissue, ultimately leading to respiratory ...

The 2025 USHL Phase II Draft is Tuesday, May 6 beginning at 11 Am CT/12 Pm ET, in partnership with Neutral Zone. The Phase I Draft was held on Monday, and the results of all 15 rounds can be found ...

The 2025 USHL Phase II Draft is Tuesday, May 6 beginning at 11 Am CT/12 Pm ET, in partnership with Neutral Zone. The Phase I Draft was held on Monday, and the results of all 15 rounds can be found ...

There have been exactly five 200-yard receiving games in Buccaneers' history, including two by future Hall of Famer Mike Evans Tampa Bay Buccaneers Head Coach Todd Bowles spoke to the media after ...

SHANGHAI, May 7, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment ...

Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a ...

The topic of mitigating cachexia is a highly topical one. This randomized phase II study, albeit negative for primary end point, provides some insights for the field and an avenue for further ...

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, announced ...